Who
Kathryn Guarini
Director
Company insider
Files Form 4 as: Director, Regeneron Pharmaceuticals.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.3M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 8 Sep 2023
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $288K400 at $719.37 | filing |
| 2 Sep 2026filed 3 Sep 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $340K400 at $850.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $288K400 at $719.37 | filing |
| 2 Sep 2026filed 3 Sep 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $340K400 at $850.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $288K400 at $719.37 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $320K400 at $800.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $288K400 at $719.37 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $320K400 at $800.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,958 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —166 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —508 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —42 at $0.00 | filing |
News
1,598 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Perpetual LtdREGN · dailypolitical.com · 15 Oct 2026Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 3.6% – Here's What HappenedREGN · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Kathryn Guarini; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.